Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month price targets for Catalyst Pharmaceuticals' stock. Their CPRX share price forecasts range from $15.50 to $24.00. On average, they expect the company's share price to reach $20.38 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.

Catalyst Pharmaceuticals' stock was trading at $18.60 at the beginning of the year. Since then, CPRX shares have decreased by 15.1% and is now trading at $15.80.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our CPRX earnings forecast.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its quarterly earnings results on Wednesday, November, 9th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. The biopharmaceutical company had revenue of $57.24 million for the quarter, compared to analysts' expectations of $53.80 million. Catalyst Pharmaceuticals had a net margin of 34.90% and a trailing twelve-month return on equity of 28.53%.

Catalyst Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $205.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.40%), Artemis Investment Management LLP (0.25%), State of New Jersey Common Pension Fund D (0.13%), Navellier & Associates Inc. (0.11%), Cyndeo Wealth Partners LLC (0.10%) and SummerHaven Investment Management LLC (0.10%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $15.80.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.64 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.61 on an earnings per share basis.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.